![]() ![]() , Complexo Antígeno L1 Leucocitário/análise , Mucosa Intestinal/diagnóstico por imagem , Doença de Crohn/tratamento farmacológico , Imageamento por Ressonância Magnética/métodos CONCLUSION: Evaluation of early transmural response by MRI is feasible and is a promising end point to monitor therapeutic efficacy in patients with CD. Early transmural response could prevent bowel damage progression over time using Clermont score (hazard ratioâ =â⁐.21 pâ =â⁐.037). CFREM was defined as Crohn's Disease Activity Index â +10% or ΔRCE > -30% was associated with a likelihood of CFREM at W52 of 84.6% vs 37.5% in patients without transmural response. MRI was performed before starting therapy, at W12 and W52. METHODS: All patients with active CD needing anti-tumour necrosis factor therapy were consecutively enrolled in this multicentre prospective study. AIMS: We aimed to assess the feasibility of early MRI evaluation (week 12 ) to predict corticosteroid-free remission at W52 and prevent long-term bowel damage. ![]() BACKGROUND: Magnetic resonance imaging is a promising tool to evaluate therapeutic efficacy in ileocolonic Crohn's disease. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |